Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
P/E ratio for Unity Biotechnology, Inc. (UBX)
P/E ratio as of 2023: -0.72
According to Unity Biotechnology, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.72. At the end of 2022 the company had a P/E ratio of -0.45.
P/E ratio history for Unity Biotechnology, Inc. from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.72 |
| 2022 | -0.45 |
| 2021 | -1.36 |
| 2020 | -2.90 |
| 2019 | -4.20 |
| 2018 | -6.02 |
| 2017 | -1.28 |
| 2016 | -1.88 |